Global Tumor Infiltrating Lymphocytes Market, By Types (Cervical Cancer, Ovarian Cancer, Kidney Cancer, Gastrointestinal Cancer, Head and Neck Cancers), Component (T-Cells, B-Cells, Natural Killer Cells), Anatomy (CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, FOXP3), End User (Hospitals, Cancer Research Centers, Clinics) – Industry Trends and Forecast to 2030.
Tumor Infiltrating Lymphocytes Market Analysis and Size
The advent of immunotherapy surveillance in cancer treatment, researchers' attention has shifted to manipulating immune cells for cancer treatment. Nowadays, the immunotherapy market is more devoted to the development of tumor-infiltrating lymphocytes to cause complete remission of tumour cells in cancer patients. The TIL therapy treatment regimen consists of a collection of lymphocytes that can destroy tumour cells. The therapy depends entirely on tumour biopsies extracted from patients rather than circulating T cells in the blood. Increasing tumour infiltrating lymphocytes adoption for cancer immunotherapy, rising success outcomes of immune cell infiltration of tumor, and increasing tumour disorders are some of the factors that will drive the growth of the tumour infiltrating lymphocytes market in the forecast period of 2023-2030.
Data Bridge Market Research analyses that the tumor infiltrating lymphocytes market which was USD 9.17 billion in 2022, is expected to reach USD 25.5 billion by 2030, at a CAGR of 12.00% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tumor Infiltrating Lymphocytes Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Cervical Cancer, Ovarian Cancer, Kidney Cancer, Gastrointestinal Cancer, Head and Neck Cancers), Component (T-Cells, B-Cells, Natural Killer Cells), Anatomy (CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, FOXP3), End User (Hospitals, Cancer Research Centers, Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Autolus Therapeutics (U.K.), Bellicum Pharmaceuticals, Inc. (U.S.), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Oxford Biomedica (U.K.), Pfizer Inc. (U.S.), Precision Biosciences (U.S.), Seeking Alpha (U.S.), bluebird bio, Inc. (U.S.), TCR² Therapeutics (U.S.), Fate Therapeutics (U.S.), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
TIL interact most closely with tumour cells and are more likely to accurately reflect tumor-host interactions. According to these findings, TIL from pulmonary tumours is similar to PBL in cell surface markers. It is widely accepted that tumor-infiltrating lymphocytes (TILs) in tumours can attack and eradicate tumour cells in cancer patients. The presence of intratumor TILs is an important piece of evidence for immune response between tumour cells and immune effector cells.
Tumor Infiltrating Lymphocytes Market Dynamics
Drivers
- Rising number of cancer patients
The growing number of cancer patients fuels demand for tumour infiltrating lymphocyte therapy, which drives market growth. According to the American Society of Clinical Oncology (ASCO), melanoma accounts for 1% of all skin cancer cases diagnosed in the United States and is responsible for the majority of skin cancer deaths.
Furthermore, promising approaches to treating various types of cancer and increased awareness about the success outcome of tumor infiltration by immune cells for various malignancies are expected to drive global market growth.
Opportunities
- Technological advancements
Research work such as the use of TILs in various cancer types also demonstrated that the combination of autologous TIL and cyclophosphamide could induce metastasis regression, among other things, have helped the market establish a landmark in the current cancer therapeutics. All of the technologies associated with the therapy, such as genome sequencing and gene editing, have assisted the therapy in delivering promising results in cancer patients, such as increased overall survival (OS), complete response rate (CR), and no chance of cancer recurrence. In this case, the therapy is thought to be one of the most significant breakthroughs for both researchers and patients.
Restraints/Challenges
- Inactive results against tumour changes
Inactive results against tumour changes due to immunoediting and therapy delays due to prolonged ex-vivo expansion are restraining factors for the growth of the tumour infiltrating lymphocytes market during the forecast period.
This tumor infiltrating lymphocytes market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tumor infiltrating lymphocytes market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Tumor Infiltrating Lymphocytes Market Scope
The tumor infiltrating lymphocytes market is segmented on the basis of types, component, anatomy and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Cervical Cancer
- Ovarian Cancer
- Kidney Cancer
- Gastrointestinal Cancer
- Head and Neck Cancers
Component
- T-Cells
- B-Cells
- Natural Killer Cells
Anatomy
- CD3
- CD8
- CD16
- CD56
- CD4
- CD57
- CD169
- CD68
- FOXP3
End User
- Hospitals
- Cancer Research Centers
- Clinics
Tumor Infiltrating Lymphocytes Market Regional Analysis/Insights
The tumor infiltrating lymphocytes market is analyzed and market size insights and trends are provided by country, type, component, anatomy and end user as referenced above.
The countries covered in the tumor infiltrating lymphocytes market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the tumor infiltrating lymphocytes market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.
Asia Pacific is anticipated to grow during the forecast period because of an increase in the number of cancer patients and government initiatives to improve health-care infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The tumor infiltrating lymphocytes market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for tumor infiltrating lymphocytes market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the tumor infiltrating lymphocytes market. The data is available for historic period 2011-2021.
Competitive Landscape and Tumor Infiltrating Lymphocytes Market Share Analysis
The tumor infiltrating lymphocytes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tumor infiltrating lymphocytes market.
Some of the major players operating in the tumor infiltrating lymphocytes market are:
- Autolus Therapeutics (U.K.)
- Bellicum Pharmaceuticals, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Novartis AG (Switzerland)
- Oxford Biomedica (U.K.)
- Pfizer Inc. (U.S.)
- Precision Biosciences (U.S.)
- Seeking Alpha (U.S.)
- bluebird bio, Inc. (U.S.)
- TCR² Therapeutics (U.S.)
- Fate Therapeutics (U.S.)
- Merck KGaA (Germany)
SKU-